DrugBank

AUGUST 9, 2024

  The average cost of bringing a new drug to market is about $2.6 When a drug loses patent protection, generic or biosimilar versions can enter the market, leading to a rapid decline in sales for the original brand-name drug. Pharmaceutical Market Analysis The global pharmaceutical market revenue in 2024 is projected to be 1.15

Pharmaceuticals 98

Pharmaceuticals Research Pharmaceutical Companies Clinical Trials 98

thought leadership

JUNE 4, 2024

Health technology developers (HTD) planning submission of a centralized Market Authorization Application (MAA) to the European Medicines Agency (EMA) should being preparing today for the implementation of the European Health Technology Assessment Regulation (HTAR).

Therapies 59

Therapies Regulations Production Marketing 59

DrugBank

SEPTEMBER 26, 2024

Due to the less extensive clinical trial requirements and the competitive nature of the biosimilar market, these biologics can be produced and marketed at significantly lower prices than their reference counterparts. Still, significant differences exist between these two major markets.

Biosimilars 98

Biosimilars Clinical Trials Production FDA 98

Codon

SEPTEMBER 29, 2024

It suggested that, in the future, certain classes of drugs, specifically genetic therapies, could be screened entirely virtually via models of life. 2028 Over the next year, the scientific community ferociously interrogated the model. The trained model also went live on HuggingFace , open for both academic and commercial usage.

Engineering 142

Engineering Virus DNA Therapies 142

Alta Sciences

AUGUST 29, 2024

Listen or read Issue 33 of The Altascientist on altasciences.com , or wherever you listen to podcasts: GROWING NEEDS FOR CNS THERAPY SOLUTIONS The different parts of the nervous system, including the brain and spinal cord and the peripheral nervous system, are important drug targets for many serious diseases affecting human health.

Drug Development 52

Drug Development Clinical Trials Small Molecule Drugs 52

The Pharma Data

JANUARY 19, 2021

TCR 2 is developing novel T-cell therapies for solid tumors and hematological cancers. The company is using its pioneering FasTCAR and TruUCAR technology platforms to discover and develop breakthrough cell therapies. The company is based in Suzhou and Shanghai, China. Ortho Clinical Diagnostics is a leader in in vitro diagnostics.

Small Molecule 52

Small Molecule Trials Laboratories Immune Response 52

Agency IQ

MAY 17, 2024

The Creating Hope Reauthorization Act would extend the expiration date of the program for another four years , from September 30, 2024 to September 30, 2028. The Give Kids a Chance Act extends the RACE for Children Act’s requirements one major step farther , applying them to combination therapies in addition to single-drug therapies.

FDA 40

FDA Disease FDA Approval Production 40